Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. more
Time Frame | EDSA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.9% | 0.31% | -1.26% |
1-Month Return | -16.32% | 0.6% | -4.16% |
3-Month Return | -63.03% | -9.44% | -0.46% |
6-Month Return | -62.5% | -5.15% | 3.58% |
1-Year Return | -65.96% | 0.33% | 22.47% |
3-Year Return | -95.68% | 4.53% | 25.13% |
5-Year Return | -93.62% | 35.98% | 77.7% |
10-Year Return | -99.95% | 100.72% | 190.12% |
Sep '20 | Sep '21 | Sep '22 | Sep '23 | Sep '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 328.80K | 500.00 | - | - | - | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":0.15,"profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Cost of Revenue | 17.60K | 118.79K | 118.19K | 183.47K | - | [{"date":"2020-09-30","value":9.59,"profit":true},{"date":"2021-09-30","value":64.74,"profit":true},{"date":"2022-09-30","value":64.42,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Gross Profit | 311.20K | (118.79K) | (118.19K) | (183.47K) | - | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":-38.17,"profit":false},{"date":"2022-09-30","value":-37.98,"profit":false},{"date":"2023-09-30","value":-58.96,"profit":false},{"date":"2024-09-30","value":"-","profit":true}] |
Gross Margin | 94.65% | (23757.60%) | (Infinity%) | (Infinity%) | - | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":-25101.29,"profit":false},{"date":"2022-09-30","value":null,"profit":false},{"date":"2023-09-30","value":null,"profit":false},{"date":"2024-09-30","value":"-","profit":true}] |
Operating Expenses | 6.71M | 13.34M | 17.59M | 9.22M | 7.01M | [{"date":"2020-09-30","value":38.16,"profit":true},{"date":"2021-09-30","value":75.84,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":52.43,"profit":true},{"date":"2024-09-30","value":39.88,"profit":true}] |
Operating Income | (6.40M) | (23.68M) | (18.37M) | (9.22M) | (7.01M) | [{"date":"2020-09-30","value":-640084200,"profit":false},{"date":"2021-09-30","value":-2368133200,"profit":false},{"date":"2022-09-30","value":-1837079000,"profit":false},{"date":"2023-09-30","value":-922275800,"profit":false},{"date":"2024-09-30","value":-701474400,"profit":false}] |
Total Non-Operating Income/Expense | 75.19K | 10.35M | 886.19K | 1.14M | 999.00K | [{"date":"2020-09-30","value":0.73,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":8.56,"profit":true},{"date":"2023-09-30","value":11,"profit":true},{"date":"2024-09-30","value":9.65,"profit":true}] |
Pre-Tax Income | (6.36M) | (13.34M) | (17.55M) | (8.37M) | (6.17M) | [{"date":"2020-09-30","value":-636343000,"profit":false},{"date":"2021-09-30","value":-1334235000,"profit":false},{"date":"2022-09-30","value":-1754812400,"profit":false},{"date":"2023-09-30","value":-837361500,"profit":false},{"date":"2024-09-30","value":-616924500,"profit":false}] |
Income Taxes | 800.00 | 800.00 | 800.00 | 800.00 | 800.00 | [{"date":"2020-09-30","value":100,"profit":true},{"date":"2021-09-30","value":100,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":100,"profit":true},{"date":"2024-09-30","value":100,"profit":true}] |
Income After Taxes | (6.36M) | (13.34M) | (17.55M) | (8.37M) | (6.17M) | [{"date":"2020-09-30","value":-636423000,"profit":false},{"date":"2021-09-30","value":-1334315000,"profit":false},{"date":"2022-09-30","value":-1754892400,"profit":false},{"date":"2023-09-30","value":-837441500,"profit":false},{"date":"2024-09-30","value":-617004500,"profit":false}] |
Income From Continuous Operations | (6.36M) | (13.34M) | (17.55M) | (8.37M) | (6.17M) | [{"date":"2020-09-30","value":-636423000,"profit":false},{"date":"2021-09-30","value":-1334315000,"profit":false},{"date":"2022-09-30","value":-1754892400,"profit":false},{"date":"2023-09-30","value":-837441500,"profit":false},{"date":"2024-09-30","value":-617004500,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true},{"date":"2024-09-30","value":"-","profit":true}] |
Net Income | (6.36M) | (13.34M) | (17.55M) | (8.37M) | (6.17M) | [{"date":"2020-09-30","value":-636423000,"profit":false},{"date":"2021-09-30","value":-1334315000,"profit":false},{"date":"2022-09-30","value":-1754892400,"profit":false},{"date":"2023-09-30","value":-837441500,"profit":false},{"date":"2024-09-30","value":-617004500,"profit":false}] |
EPS (Diluted) | (0.74) | (1.70) | (1.05) | (0.95) | (1.93) | [{"date":"2020-09-30","value":-74,"profit":false},{"date":"2021-09-30","value":-170,"profit":false},{"date":"2022-09-30","value":-105,"profit":false},{"date":"2023-09-30","value":-95,"profit":false},{"date":"2024-09-30","value":-193,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
EDSA | |
---|---|
Cash Ratio | 0.57 |
Current Ratio | 0.91 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EDSA | |
---|---|
ROA (LTM) | -71.52% |
ROE (LTM) | -129.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EDSA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.48 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EDSA | |
---|---|
Trailing PE | NM |
Forward PE | 0.17 |
P/S (TTM) | 120477.93 |
P/B | 3.03 |
Price/FCF | NM |
EV/R | 128525.38 |
EV/Ebitda | NM |
Edesa Biotech Inc (EDSA) share price today is $1.5899
Yes, Indians can buy shares of Edesa Biotech Inc (EDSA) on Vested. To buy Edesa Biotech Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EDSA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Edesa Biotech Inc (EDSA) via the Vested app. You can start investing in Edesa Biotech Inc (EDSA) with a minimum investment of $1.
You can invest in shares of Edesa Biotech Inc (EDSA) via Vested in three simple steps:
The 52-week high price of Edesa Biotech Inc (EDSA) is $5.99. The 52-week low price of Edesa Biotech Inc (EDSA) is $1.55.
The price-to-earnings (P/E) ratio of Edesa Biotech Inc (EDSA) is
The price-to-book (P/B) ratio of Edesa Biotech Inc (EDSA) is 3.03
The dividend yield of Edesa Biotech Inc (EDSA) is 0.00%
The market capitalization of Edesa Biotech Inc (EDSA) is $5.51M
The stock symbol (or ticker) of Edesa Biotech Inc is EDSA